ArticleAnnals of translational medicine2022

Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer.

Roberta Maltoni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.